Company Overview and News

Zeta Resources bid for NZ Oil & Gas fails, H&G plans to accept Ofer Group Oil & Gas' offer

Private investment firm H&G will accept Ofer Group Oil & Gas' offer for New Zealand Oil & Gas after ASX-listed Zeta Resources' play to seize control of the company did not meet the minimum acceptance condition and has lapsed.
Upvote Downvote

Zeta makes partial takeover bid for New Zealand Oil & Gas

2017-08-11 ogj
Singapore-based Zeta Energy Pte. Ltd., a wholly owned subsidiary of investment group Zeta Resources Ltd., has launched a partial offer for Wellington-based New Zealand Oil & Gas Ltd. (NZOG). If successful, Zeta would gain a 50.1% controlling interest in NZOG.
Upvote Downvote

Woodside stepping up exploration program offshore Myanmar

2017-04-25 ogj
Woodside Petroleum Ltd., Perth, plans to drill five wells offshore Myanmar in 2017, one more than originally scheduled, following encouraging results in 2016.
Upvote Downvote

Timor Resources secures Timor-Leste onshore permits

2017-04-21 ogj
Timor Resources Holdings (TRH), a member of New South Wales engineering company Nepean Group, has been awarded two onshore oil and gas permits in Timor-Leste.
Upvote Downvote

MARKET WATCH: NYMEX, Brent oil prices drop about $2/bbl on gasoline build - Oil & Gas Journal

2017-04-20 ogj
The light, sweet crude oil prices for May delivery fell nearly $2/bbl on the New York market Apr. 19 while Brent crude oil for June delivery also fell nearly $2/bbl on the London market after an unexpected build in US gasoline inventories.
Upvote Downvote

EPA reconsiders methane emissions rule, stays compliance date

2017-04-19 ogj
The US Environmental Protection Agency will reconsider its rule covering methane emissions from new, reconstructed, and modified oil and gas sources, and stay the regulation’s June 3 compliance date for 90 days while it takes comments, it announced on Apr. 19.
Upvote Downvote

Report recommends a fresh look at global energy governance groups

2017-04-19 ogj
The International Energy Agency and other global organizations that were created in response to crude-oil supply disruptions in the 1970s may need to be refocused and reformed, a recent Atlantic Council report suggested. Dramatic supply-demand balance changes in the wake of significant technological breakthroughs and the emergence of China, India, and other economic growth powerhouses have created new issues to be addressed, the report said.
Upvote Downvote

Galoc field awaits sidetrack in untested Mid Area off the Philippines - Oil & Gas Journal

2017-04-19 ogj
Commercial potential for the Galoc Mid Area on Block C1 offshore the Philippines remains inconclusive according to Galoc Production Co. WLL, a subsidiary of Nido Petroleum Ltd., Perth. The operator reported that its Galoc-7 well in Contract Area 14 encountered its reservoir objective between 2,240-2,358 m MD with a gross pay of 115 m and net sand thickness of 8 m comprising poor quality sandstone and claystone (OGJ Online, Apr.
Upvote Downvote

McKinsey identifies oil supply, demand scenarios to 2030

2017-04-19 ogj
McKinsey Energy Insights (MEI), an energy data and analytics specialist in London, has released its latest Global Oil Supply and Demand Outlook to 2030, which identifies five potential supply and demand scenarios.
Upvote Downvote

MARKET WATCH: Crude prices declining on US supply, inventory data - Oil & Gas Journal

2017-04-19 ogj
Benchmark crude oil prices continued modest declines on the New York and London markets Apr. 18 as concerns persisted about oversupply from the US. The losses continued into early Apr. 19 after weekly inventory data released by the US Energy Information Administration failed to change market sentiment.
Upvote Downvote

Pan Pacific Petroleum NL secures US$5M from asset sale to Repsol

Pan Pacific Petroleum NL (ASX:PPP) has agreed to sell its 5% interest in Block 07/03 located in the Nam Con Son Basin in the South China Sea, to Repsol Exploracion S.A for US$5 million.
Upvote Downvote

Pan Pacific Petroleum in an ASX trading halt

Pan Pacific Petroleum (ASX:PPP) has been granted a trading halt by the ASX, pending details regarding the disposal of the company’s major undertaking venture.
Upvote Downvote

Tamarind gains sole ownership of Tui fields in New Zealand

2017-02-15 ogj
Private Malaysian oil and gas company Tamarind Management Sdn. Bhd. has completed its buyout of interest holders in Tui oil fields offshore New Zealand’s north island. Tamarind now has 100% ownership of the field.
Upvote Downvote

Yinson bags conditional award for Vietnam FPSO contract

2017-01-23 theedgemarkets
KUALA LUMPUR (Jan 23): Yinson Holdings Bhd secured a conditional award for the supply of a floating production, storage and offloading (FPSO) facility to Vietnam's Ca Rong Do oil and gas offshore field. 
Upvote Downvote

NZOG considers exit from Tui oil field after offer from Blackstone-backed Tamarind

New Zealand Oil & Gas says it's considering an offer to buy its 27.5 per cent interest in the Tui oil field after Tamarind, an energy company backed by Blackstone Energy Partners, agreed to buy the 57.5 per cent stake held by field operator AWE for US$1.5 million.
Upvote Downvote

Related Articles

GNCA: Genocea Biosciences Analysis and Research Report

11h - Asif

Overview Genocea Biosciences is a biopharmaceutical company that discovers and develops novel cancer vaccines. The company use its proprietary discovery platform, ATLAS, to recall a patient’s pre-existing CD4+ and CD8+ T cell immune responses to their tumor to identify antigens for inclusion in vaccines that are designed to act through T cell (or cellular) immune responses. The company believe that using ATLAS to identify antigens for inclusion in cancer vaccines could lead to more immunogenic and efficacious cancer vaccines. In September 2017, the company announced a strategic shift to immuno-oncology and a focus on the development of neoantigen cancer vaccines. Currently, all of its research programs and product candidates in active development are at the preclinical stage. The company's most advanced program is its preclinical immuno-oncology program, GEN-009, a neoantigen cancer vaccine. The GEN-009 program uses ATLAS to identify patient neoantigens, or newly formed anti...

AMZN:, Inc Analysis and Research Report

12h - Asif

Overview opened its virtual doors on the World Wide Web in July 1995. The company seek to be Earth’s most customer-centric company. Amazon is guided by four principles: customer obsession rather than competitor focus, passion for invention, commitment to operational excellence, and long-term thinking. In each of its segments, the company serve its primary customer sets, consisting of consumers, sellers, developers, enterprises, and content creators. In addition, the company provide services, such as advertising services and co-branded credit card agreements. Amazon has organized its operations into three segments: North America, International, and Amazon Web Services (“AWS”). These segments reflect the way the Company evaluates its business performance and manages its operations. Additional information on its operating segments and its net sales is contained in Item 8 of Part II, “Financial Statements and Supplementary Data—Note 11—Segment Information.” The compan...

LPCN: Lipocine Inc Analysis and Research Report

2018-04-23 - Asif

Overview Lipocine is a specialty pharmaceutical company focused on applying its oral drug delivery technology for the development of pharmaceutical products in the area of men’s and women’s health. The company's proprietary delivery technologies are designed to improve patient compliance and safety through orally available treatment options. The company's primary development programs are based on oral delivery solutions for poorly bioavailable drugs. Lipocine has a portfolio of proprietary product candidates designed to produce favorable pharmacokinetic (“PK”) characteristics and facilitate lower dosing requirements, bypass first-pass metabolism in certain cases, reduce side effects, and eliminate gastrointestinal interactions that limit bioavailability. The company's lead product candidate, TLANDO™, is an oral testosterone replacement therapy (“TRT”) and is currently under review by the United States Food and Drug Administration (“FDA”) with a Prescription Drug User Fee Act (“...